Trial Profile
A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents Aged 13-17 Years With ADHD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2017
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Noven Therapeutics
- 21 May 2009 Results preseneted at the 162nd Annual Meeting of the American Psychiatric Association
- 21 May 2009 Primary endpoint results presented at the 162nd Annual Meeting of the American Psychiatric Association
- 23 Dec 2008 Planned number of patients changed from 250 to 290 as reported by ClinicalTrials.gov.